Latest News for: tregs

Edit

Taiwan Bio partners with Terumo Blood and Cell Technologies to advance automated Treg manufacturing on Quantum Flex (Terumo Corporation)

Public Technologies 18 Mar 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 130251989) .
Edit

Taiwan Bio partners with Terumo Blood and Cell Technologies to advance automated Treg manufacturing on Quantum Flex

Pharmiweb 17 Mar 2026
... new process for next-generation engineered Treg manufacturing ... "As a rare, difficult-to-expand, and inherently unstable cell type, Tregs make manufacturability a defining consideration.
Edit

PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes

Nasdaq Globe Newswire 10 Mar 2026
PTG), a pioneer and global leader in the development of therapies ...
Edit

Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid ...

Nasdaq Globe Newswire 03 Mar 2026
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has ...
Edit

Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE ...

Nasdaq Globe Newswire 03 Mar 2026
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered ...
Edit

Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval (Syncona Ltd)

Public Technologies 03 Mar 2026
QEL-005 is a novel product candidate built on Quell's proprietary Phenotype Locked™ CAR-Treg platform ... We believe that using CAR-Tregs, that are natural tissue regulators, we will be able to achieve deep and durable disease control and achieve a cure.
Edit

Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study (Syncona Ltd)

Public Technologies 03 Mar 2026
The LIBERATE trial investigates the ability of QEL-001, a phenotype-locked anti-HLA-A2 CAR-Treg autologous cell therapy candidate, to facilitate weaning of standard-of-care immunosuppression (IS) in patients who have undergone liver transplantation.
Edit

Kincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for ...

Enid News & Eagle 10 Feb 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Feb 10, 2026-- ... .
Edit

TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics

The Milton Standard Journal 27 Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 27, 2026-- ....
Edit

Regulatory T-Cell (Tregs) Therapies Market Size to Reach USD 320.4 million in 2032

Pharmiweb 13 Jan 2026
Source Outlook (Revenue, USD Million; 2022-2032) Autologous Tregs Allogeneic Tregs Therapeutic Type Outlook (Revenue, USD Million; 2022-2032) Polyclonal Tregs Antigen-Specific Tregs CAR-Tregs ...
Edit

Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases

Pharmiweb 13 Jan 2026
This license agreement further expands Immuthera’s growing portfolio of internally generated Treg, engineered CAR-Treg, multi-edited/allogeneic CAR-Treg, and in-vivo generated antigen-specific Treg ...
Edit

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement ...

The Eagle-Tribune 08 Jan 2026
HOUSTON--(BUSINESS WIRE)--Jan 8, 2026-- ... .
Edit

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Pharmiweb 08 Jan 2026
Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and sustained through the 22-week treatment period.
Edit

FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis

PR Newswire 06 Jan 2026
6, 2026 /PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf, regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, announced that the U.S.
Edit

CUHK unveils the world’s first CD4+ Treg cell heart regeneration mechanism Offering a new target for heart repair treatment (The Chinese University of Hong Kong)

Public Technologies 02 Jan 2026
CUHK unveils the world's first CD4+ Treg cell heart regeneration mechanism ... CU Medicine announces the world's first discovery that CD4+ Treg cells are not only the 'peacekeepers' of the human immune system but also act as 'repair crews'.

Article Search

tools
×
×
×
×